Lightlake Therapeutics Inc., an early stage biopharmaceutical company developing modern addiction treatments based on its expertise using opioid antagonists, announced today compelling final data from a Phase II study of the Company's proprietary opioid antagonist naloxone nasal spray treatment for patients with Binge Eating Disorder (BED).
URL: http://www.news-medical.net/news/20120809/Lightlake-announces-final-data-from-naloxone-nasal-spray-Phase-II-study-on-Binge-Eating-Disorder.aspx
No comments:
Post a Comment